Effect of pravastatin treatment on Chlamydia pneumoniae infection, inflammation and serum lipids in NIH/S mice

被引：8
|
作者：
Tiirola, Terttu
Jauhiainen, Matti
Erkkila, Leena
Bloigu, Aini
Leinonen, Maija
Haasio, Kristiina
Laitinen, Kirsi
Saikku, Pekka
机构：
[1] Natl Publ Hlth Inst, Dept Mol Med, FI-00251 Helsinki, Finland
[2] Orion Pharma, Espoo, Finland
[3] Univ Helsinki, Dept Publ Hlth, Helsinki, Finland
[4] Univ Oulu, Dept Med Microbiol, Oulu, Finland
来源：
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS | 2007年 / 29卷 / 06期
关键词：
D O I：
10.1016/j.ijantimicag.2007.02.001
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：741 / 742
页数：2
相关论文
共 50 条
  • [21] The association of carotid plaque inflammation and Chlamydia pneumoniae infection with cerebrovascular symptomatology
    Kaperonis, Elias A.
    Liapis, Christos D.
    Kakisis, John D.
    Perrea, Despina
    Kostakis, Alldviadis G.
    Karayannakos, Panayotis E.
    JOURNAL OF VASCULAR SURGERY, 2006, 44 (06) : 1198 - 1204
  • [22] Synergetic effect of Chlamydia pneumoniae infection and OxLDL on VSMC
    Dibrov, E.
    Hirono, S.
    Paul, C.
    Pierce, G.
    FEBS JOURNAL, 2007, 274 : 187 - 187
  • [23] The effect of Chlamydia pneumoniae infection on serum lipid profile: A systematic review and meta-analysis
    Mohammadzadeh, Elahe
    Jalali-Jalalabadi, Hoda
    Abdolahinia, Elaheh Dalir
    Narimisa, Negar
    GENE REPORTS, 2022, 27
  • [24] Chlamydia pneumoniae infection as a trigger for a Cagan's syndrome
    Lepur, D
    Vranjican, Z
    Himbele, J
    Klinar, I
    Barsic, B
    JOURNAL OF INFECTION, 2006, 52 (03) : 223 - 226
  • [25] Effect of simvastatin, an established lipid-lowering drug, on pulmonary Chlamydia pneumoniae infection in mice
    Erkkilä, L
    Jauhiainen, M
    Laitinen, K
    Haasio, K
    Tiirola, T
    Saikku, P
    Leinonen, M
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (09) : 3959 - 3962
  • [26] Chlamydia pneumoniae infection is not an independent risk factor for development of atherosclerosis in normolipidemic mice and acceleration of the development of lesions in hyperlipidemic mice is unique to Chlamydia pneumoniae
    Blessing, E
    Nagano, S
    Campbell, LA
    Rosenfeld, ME
    Kuo, CC
    CIRCULATION, 2000, 102 (18) : 54 - 54
  • [27] Systemic and mucosal antibody response in experimental Chlamydia pneumoniae infection of mice
    Penttila, Tuula
    Wahlstrom, Eva
    Vuola, Jenni M.
    Sarvas, Matti
    Puolakkainen, Mirja
    COMPARATIVE MEDICINE, 2006, 56 (04) : 272 - 278
  • [28] Discovery of a vaccine antigen that protects mice from Chlamydia pneumoniae infection
    Thorpe, Callum
    Edwards, Lorna
    Snelgrove, Robert
    Finco, Oretta
    Rae, Aaron
    Grandi, Guido
    Guilio, Ratti
    Hussell, Tracy
    VACCINE, 2007, 25 (12) : 2252 - 2260
  • [29] The role of inflammation and Chlamydia pneumoniae infection in patients with chronic occlusion of the terminal aorta
    Tilea, I
    Brindusa, Tilea
    Gratiela, Tripon
    Maria, Tatar Cristina
    Serban, R. C.
    Suciu, H.
    Alina, Scridon
    REVISTA ROMANA DE MEDICINA DE LABORATOR, 2008, 12 (03): : 31 - 36
  • [30] Bronchial Chlamydia pneumoniae infection, markers of allergic inflammation and lung function in children
    Schmidt, SM
    Müller, CE
    Bruns, R
    Wiersbitzky, SKW
    PEDIATRIC ALLERGY AND IMMUNOLOGY, 2001, 12 (05) : 257 - 265
12345